peppersite
Metabolic supportsubcutaneous

CagriSema

CagrilintideSemaglutide

CagriSema is an investigational fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist, given once weekly. It has been studied for weight management in people in Phase 3 trials and is not FDA-approved as of June 2026.

A blend, not a compound

This is a combination sold as one vial. It has not been studied as a single substance, so what is known is what is known about each part, linked above. Sources that report a dose for the blend report it for that mixture, not for any component on its own.

Researched for
Metabolic HealthBody CompositionWeight ManagementAppetite Regulation

At a glance

Type
Metabolic support
Given by
subcutaneous
Evidence
Not yet audited here; the reference library calls it human data available
Reported amount
Sources differ. See the source

How much to draw

Full calculator →
Your draw
–units
Fill in the three numbers to see the draw.
Amount per dose

The reference does not report a single injectable amount for CagriSema, so the amount is yours to enter. The arithmetic is the same for any vial. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for CagriSema or for anything else, and nothing below has been checked against the study it came from.

cagrilintide 2.4 mg + semaglutide 2.4 mg
Frequency
Once weeklyREDEFINE trials ran 68 weeks; research cycles are commonly 12-24 weeks; short investigative cycles 8-12 weeks.
Route
Subcutaneous
Reported by
peptidedosingprotocols.com
What it says[Source: peptidedosingprotocols.com]
Reconstitution, as reported
  • 1. Wash your hands and lay out a clean work surface. 2. Wipe the rubber stopper of each vial with an alcohol swab and let it dry. 3. Draw the planned BAC water volume into a fresh syringe. 4. Inject the BAC water down the inside wall of the peptide vial, do not spray directly onto the lyophilized powder. 5. Swirl gently until the powder is fully dissolved. Do not shake. 6. Label the vial with the date of reconstitution and the concentration. 7. Refrigerate at 36-46°F (2-8°C) and use within the supplier-specified stability window. For pre-blended vials: BAC water volume is dictated by the vial concentration printed on the COA, there is no universal default for a fixed-dose combination, so verify the supplier's spec before reconstituting. Illustrative examples: 20 mg vial + 2.0 mL BAC water = 10 mg/mL (0.48 mL = 48 units U-100 per weekly maintenance draw); 20 mg vial + 2.5 mL BAC water = 8 mg/mL (0.60 mL = 60 units U-100); 20 mg vial + 3.0 mL BAC water = 6.67 mg/mL (0.72 mL = 72 units U-100). For separate vials: reconstitute each compound independently; e.g. 5 mg vial + 2.0 mL BAC water = 2.5 mg/mL (0.96 mL = 96 units U-100 per 2.4 mg draw); 10 mg vial + 3.0 mL BAC water = 3.33 mg/mL (0.72 mL = 72 units U-100 per 2.4 mg draw).
Not yet audited

We have not published an audit on CagriSema. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

CagriSema combines two compounds that both increase fullness and slow stomach emptying, but through different receptors. Researchers link this to cagrilintide acting on amylin and calcitonin receptors and semaglutide acting on the GLP-1 receptor. In the REDEFINE 1 trial, average weight loss was 20.4% with the combination versus 14.9% with semaglutide alone and 11.5% with cagrilintide alone.

In technical termsCombines amylin-receptor agonism (cagrilintide) with GLP-1 receptor agonism (semaglutide); studied for appetite regulation and weight management.

Reported side effects

Seen in studies: gut events were the most common, mostly mild to moderate and concentrated during dose escalation. In REDEFINE 1 they were reported by 79.6% of people on CagriSema versus 39.9% on placebo, including nausea (55% vs 12.6%), constipation (30.7% vs 11.6%) and vomiting (26.1% vs 4.1%). In REDEFINE 2, in adults with type 2 diabetes, the rate was 72.5% versus 34.4%. People stopping because of adverse events came to 5.9% and 8.4% on CagriSema in the two trials, versus 3.5% and 3% on placebo.

Not ruled out: identity, purity and contamination problems in any non-approved or compounded product, since CagriSema is investigational. No published trial has compared it with a compounded equivalent.

What gets monitored

HbA1c (noted as an outcome in REDEFINE 2: 73.5% reached HbA1c ≤6.5%); at-home blood test referenced via SiPhox Health. (reported by peptidedosingprotocols.com)

Common questions

Is CagriSema FDA-approved?

No. As of June 2026, CagriSema is not FDA-approved. Novo Nordisk submitted a New Drug Application on December 18, 2025, with FDA review expected during 2026, so it remains investigational.

What is the CagriSema dose used in clinical trials?

The REDEFINE 1 and REDEFINE 2 Phase 3 trials used cagrilintide 2.4 mg with semaglutide 2.4 mg once weekly under the skin. That dose was reached after roughly 16 weeks of titration, which began at 0.25 mg of each compound and stepped up every 4 weeks.

How much weight loss did CagriSema produce in REDEFINE 1?

Adults with obesity or overweight and no diabetes had a mean weight reduction of 20.4% at 68 weeks, compared with 3.0% on placebo. That figure uses the treatment-policy estimand. Under the trial-product estimand, the reduction was 22.7%.

What is the difference between the treatment-policy and trial-product estimands?

The treatment-policy estimand measures the effect whether or not participants stayed on treatment or used rescue therapies. The trial-product estimand measures the effect if participants stayed on treatment as intended. That is why the REDEFINE 1 result reads as 20.4% under one and 22.7% under the other.

How does CagriSema compare to tirzepatide?

Both produce large average weight loss in obesity. In a head-to-head open-label trial reported in February 2026, average weight loss at 84 weeks favored tirzepatide, and CagriSema did not meet its non-inferiority target. As of June 2026, tirzepatide is FDA-approved and CagriSema is not.

What are the most common CagriSema side effects?

Gut events were the most common in both REDEFINE trials. In REDEFINE 1 they were reported by 79.6% of CagriSema participants versus 39.9% on placebo, including nausea (55%), constipation (30.7%) and vomiting (26.1%). Symptoms typically peaked during dose escalation and eased during maintenance.

How long is a typical CagriSema research cycle?

REDEFINE 1 and REDEFINE 2 ran 68 weeks, with roughly the first 16 weeks spent on dose titration. The source says many research planning windows are shorter, with 12 to 24 weeks common for tolerability and titration assessment. It notes that shorter cycles show proportionally smaller weight changes than the full-length trial numbers.

Does CagriSema improve blood sugar in addition to weight?

Yes, in adults with type 2 diabetes. In REDEFINE 2, 73.5% of CagriSema participants reached an HbA1c of 6.5% or lower, versus 15.9% on placebo. Sponsor-reported REIMAGINE 2 data described an HbA1c reduction of 1.91 percentage points alongside 14.2% weight loss.

Sources

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things
Cagrilintide / Retatrutide

Cagrilintide / Retatrutide is a combination of cagrilintide, an amylin analog, and retatrutide, a triple GLP-1, GIP and glucagon agonist, sold pre-blended in one vial or as separate vials. It is discussed for weight management, and no clinical trial has tested the two together.

Cagrilintide / Tirzepatide

Cagrilintide / Tirzepatide is a combination of cagrilintide, an amylin analog, and tirzepatide, a dual GIP and GLP-1 agonist, each given once weekly from its own vial. It is discussed for weight management, with one study in obese rats and no human trial of the two together.

Mazdutide

Mazdutide, also called IBI362, is an investigational lab-made peptide drug that switches on two metabolic hormone receptors at once. It is being studied in clinical trials as a once-weekly injection for weight management and metabolic health.

Retatrutide

Retatrutide is an investigational once-weekly injectable that acts on three hormone receptors at once: GLP-1, GIP and glucagon. It is being studied for weight and metabolic outcomes in adults with obesity, type 2 diabetes and fatty liver disease.

Semaglutide

Semaglutide is a lab-made copy of GLP-1, a gut hormone that helps the body manage hunger and blood sugar. It is among the most heavily studied weight-loss and diabetes medicines, with trial programmes covering more than 45,000 participants.

Tirzepatide

Tirzepatide is a lab-made peptide that switches on two gut-hormone receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It is studied in people for weight management and blood sugar control, including in the SURPASS and SURMOUNT trial programs.